Enveda Biosciences
Boulder biotech mining natural-product chemistry with mass-spec AI; oral atopic-dermatitis drug ENV-294 in Phase 2.
1. Core Product / Service
Enveda (founded 2019, Boulder, CO) maps the chemistry of natural sources with high-throughput mass spectrometry and machine learning, then develops the resulting small molecules as its own drugs [1]. Its PRISM foundation model is reported to be trained on ~1.2B mass spectra; since 2019 the platform has produced 17 development candidates, three of which have reached humans (ENV-294, ENV-308, ENV-6946) [2].
Lead asset — ENV-294, an oral first-in-class therapy for atopic dermatitis and asthma. A 9-patient Phase 1b cohort showed a mean EASI reduction of 85% (company data) [1]. Parallel Phase 2a studies in atopic dermatitis and asthma began in December 2025 [3]; the Phase 2a (NCT07298395) is expected to complete its primary endpoint around December 2026, and a ~200-patient Phase 2b dose-ranging study (NCT07643766) started in June 2026 [1][4]. ENV-308 (weight maintenance after GLP-1 discontinuation) and ENV-6946 (IBD) are only described in secondary sources [1].
Wet lab. Enveda builds its data in-house across two sites [5]:
| Site | Size | Role |
|---|---|---|
| Boulder, CO (Flatiron Park) | ~60,000 sf (builder's project page: ~49,000 sf) | Discovery and development; Hamilton STAR / Vantage sample automation |
| Hyderabad, India (Genome Valley) | ~24,000 sf | Lead-optimization medicinal chemistry lab |
Global headcount was ~250 in November 2024 [5]. Named CRO/CMO partners have not been disclosed.
2. Target Users & Pain Points
- Its own pipeline — inflammation/immunology (atopic dermatitis, asthma, IBD) and metabolic indications.
- Pain addressed: natural products are a historically rich source of drugs, but most of their chemical space is uncharacterized; Enveda's bet is that mass-spec plus ML can annotate "dark" metabolites at scale and turn them into tractable oral small molecules.
3. Competitive Landscape
| Player | Approach | Vs. Enveda |
|---|---|---|
| recursion-pharmaceuticals | Phenomic screening + chemistry | Target-agnostic biology data vs. chemistry-first data |
| insilico-medicine | Generative chemistry, many Phase 1/2 assets | Designs molecules de novo; Enveda starts from nature |
| iambic-therapeutics | Automated DMTA, oncology small molecules | Also small-molecule, but synthetic-library chemistry |
4. Unique Observations
- Furthest-along clinical asset in its cohort: among US AI-native pipeline companies founded around 2019–2024, ENV-294 in Phase 2a/2b is ahead of iambic-therapeutics (Phase 1/1b), retro-biosciences (Phase 1) and xaira-therapeutics / newlimit (preclinical) [1].
- Mid-sized lab footprint: Boulder plus Hyderabad (~73–84k sf combined) sits in the 50–90k sf band that most $100M–$1B-funded US pipeline startups occupy — a single mid-size biotech building, not a pharma campus [5].
- Facility data are dated: both the 60k sf Boulder and 24k sf Hyderabad figures originate from 2022 announcements; a 2024 local news report confirms Boulder at 60k sf, while current Hyderabad status rests on ongoing job postings rather than a recent primary source [1][5].
- US-India split: putting med-chem in Hyderabad is an in-house version of the cost arbitrage other US biotechs buy from Asian CROs.
5. Financials / Funding
- Series D: $150M (September 2025) [1].
- Series E: $311M (September 2026), led by Catalio Capital; new investors include Durable Capital, ICONIQ and Lightspeed; reported valuation ~$2B [2][6]. Use of proceeds includes later-stage trials for ENV-294 and ENV-308 and expanding the automated labs behind PRISM [2].
- Total raised: >$845M (company) [2].
6. People & Relationships
- Founder & CEO: Viswa Colluru (formerly at Recursion) [1].
- Board: Mikael Dolsten (former Pfizer CSO) [1].
- Investors: Catalio, Durable, ICONIQ, Lightspeed.
- Peers: recursion-pharmaceuticals, insilico-medicine, iambic-therapeutics.
Sources
- [1] Enveda press releases (Series D, Phase 1b data) and pipeline disclosures, cross-checked against trial registries (accessed 2026-10-14)
- [2] Business Wire, "Enveda Raises $311 Million…" (2026-09-23; accessed 2026-10-14)
- [3] Business Wire, "Enveda Initiates Phase 2 Clinical Trials of ENV-294…" (2025-12-09; accessed 2026-10-14)
- [4] ClinicalTrials.gov NCT07298395, NCT07643766 (2026-10-14)
- [5] Business Wire facility announcement (2022-04-07); BizWest (2024-11); builder project page (accessed 2026-10-14)
- [6] BioPharma Dive, Enveda Series E coverage (2026-10-14)